Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26

16 ноября 2026 г. обновлено: Triastek, lnc.

This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26.

Three treatments, as described below, are planned:

Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval.

This study consists of three periods: a screening period (Day -7~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 ~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).

Обзор исследования

Статус

Еще не набирают

Тип исследования

Интервенционный

Регистрация (Оцененный)

18

Фаза

  • Фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Junya Yu
  • Номер телефона: 18752010068
  • Электронная почта: yujunya@triastek.com

Места учебы

    • NA, Municipality
      • Chongqing, NA, Municipality, Китай, 400020
        • No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
        • Контакт:
          • Liangying Liu
          • Номер телефона: +86-13436012840
          • Электронная почта: 37145266@qq.com

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Да

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Healthy male and female participants aged 18 years and above (including 18 years).

  2. Male participants with body weight ≥50.0 kg and female participants with body weight ≥45.0 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), within the range of 18.5-30.0 kg/m² (inclusive).

  3. Participants with no history of chronic or serious diseases of the cardiovascular, digestive, urinary, respiratory, hematologic/lymphatic, endocrine, immune, psychiatric, or nervous systems, and in good general health.

  4. Participants must be willing to use effective contraception from screening until 2 months after the last dose of the final treatment cycle.

    a) Female participants must: i. Be of non-child-bearing potential i.e. surgically sterilized or postmenopausal, or ii. If of child-bearing potential, must have a negative pregnancy test at Screening and within 24 hours prior to treatment Day 1. They must agree not to attempt to become pregnant, must not donate ova, and must agree to use two forms of highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug, OR use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent, during the study, and at least 2 months after the last dose of study drug.

    iii. Women of childbearing potential (WCBP) with same sex partners who abstain from penile- vaginal intercourse are eligible if such is their preferred and usual lifestyle.

    c) Male participants must: i. Be willing not to donate sperm until at least 2 months after the last dose of study drug and.

    ii. If engaging in sexual intercourse with a female partner who could become pregnant, be willing to use a condom in addition to having the female partner use a highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug.

  5. Voluntarily sign an informed consent form prior to the trial, with full understanding of the trial content, procedures, and potential adverse reactions, and be able to communicate effectively with investigators.

  6. Capable of completing the study in accordance with the trial protocol requirements.

Exclusion Criteria:

  1. Vital signs, physical examination, hearing assessment, laboratory tests (hematology, urinalysis, blood chemistry, coagulation panel), infectious disease panel, 12-lead ECG, etc., showing clinically significant abnormalities;
  2. (Inquiry) Smoking 5 or more cigarettes per day on average within 3 months prior to screening, or unable to refrain from using any tobacco product within 48 h prior to administration and during hospitalization;
  3. (Inquiry) History of acute infectious disease with significant antibiotic use within 3 months before screening, or mild infectious disease within 7 days before first dose;
  4. (Inquiry) History of allergy to itraconazole, other azoles, or any excipients of the investigational product, or allergy to two or more substances;
  5. (Inquiry) Alcohol consumption >14 units per week within 3 months before screening (1 unit = 17.7 mL ethanol, equivalent to ~354 mL of 5% beer, ~44 mL of 40% spirits, or ~147 mL of 12% wine), or unable to abstain from alcohol-containing products during the study, or positive alcohol breath test;
  6. (Inquiry) Received blood transfusion, donated blood, or experienced major blood loss (≥400 mL) within 3 months before first dose;
  7. (Inquiry) Vaccinated within 14 days before first dose, or planning vaccination during the study period;
  8. (Inquiry) Taken any prescription medication, over-the-counter medication, vitamin products, or herbal supplements within 2 weeks before first dose;
  9. (Inquiry) Participants who, within 72 hours prior to the first dose, have consumed special diet (including dragon fruit, mango, grapefruit, etc.), or consumed foods or beverages containing caffeine or rich in xanthine (such as chocolate, strong tea, coffee, cola, animal offal), engaged in vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion;
  10. (Inquiry + System Search) Used other investigational products or participated in clinical drug trials within 3 months before first dose;
  11. Experienced acute illness or required concomitant medication from screening until first dose;
  12. Female participants who are breastfeeding or have a positive pregnancy test results at screening or during the study period;
  13. History of drug abuse within the past year, or illicit drug use within 3 months before screening, or positive drug abuse screening test;
  14. (Inquiry) Dysphagia, lactose intolerance (e.g., history of diarrhea after milk consumption), or inability to comply with standardized diet;
  15. (Inquiry) History of diseases that may affect safety or pharmacokinetics of the investigational product, such as gastric spasms, gastroesophageal reflux disease, Crohn's disease, chronic atrophic gastritis, Sjögren's syndrome, pernicious anemia, etc., or currently having any of these conditions;
  16. (Inquiry) Post-partial gastrectomy, or major surgery within 6 months before screening, or planning surgery during the study, or history of surgery affecting drug absorption, distribution, metabolism, or excretion (except appendectomy);
  17. (Inquiry + System Search) History of serious conditions judged by the investigator as clinically significant in the cardiovascular system (including congestive heart failure, coronary atherosclerotic heart disease, valvular heart disease, arrhythmia, torsades de pointes), hepatic system (active liver disease), urinary system, digestive system, respiratory system (including chronic obstructive pulmonary disease, cystic fibrosis), hematologic/lymphatic system (e.g., neutropenia), nervous system, psychiatric system, visual disorders/abnormalities, auditory disorders (including tinnitus and sudden deafness), malignant tumors, or currently having any of these conditions;
  18. (Inquiry) Use of any drugs known to interact with itraconazole within 4 weeks before screening [including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (e.g., dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, levacetylmethadol (levomethadyl), halofantrine, astemizole, mizolastine, terfenadine, sertindole, bepridil, lercanidipine, ivabradine, domperidone, colchicine, fesoterodine, telithromycin, solifenacin, erythromycin, clarithromycin, etc.];
  19. (Inquiry) Female participants who have used long-acting estrogen or progestogen injections or implants within 6 months before the study, or short-acting contraceptives within 30 days before the study;
  20. (Inquiry) History of vasovagal syncope from blood or needles, or unable to tolerate venipuncture;
  21. Participants unable to complete the study due to other reasons;
  22. Participants judged by the investigator to have other factors unsuitable for participation in this study;
  23. Participants with creatinine clearance <80 mL/min (calculated using Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.818 × serum creatinine (μmol/L)]; for females, multiply result by 0.85);
  24. (Inquiry) Participants with decreased gastric acidity, such as participants taking gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or participants with achlorhydria caused by certain diseases.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Назначение кроссовера
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Tfasted-Tfed-R group

Test Product

Reference Product

Экспериментальный: Tfasted-R-Tfed group

Test Product

Reference Product

Экспериментальный: Tfed-Tfasted-R group

Test Product

Reference Product

Экспериментальный: Tfed-R-Tfasted group

Test Product

Reference Product

Экспериментальный: R-Tfasted-Tfed group

Test Product

Reference Product

Экспериментальный: R-Tfed-Tfasted group

Test Product

Reference Product

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Cmax
Временное ограничение: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-tlast
Временное ограничение: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-inf
Временное ограничение: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Tmax
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
t₁/₂
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Kel
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
F
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
CL/F
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Vz/F
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
AUC_%Extrap
Временное ограничение: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Оцененный)

16 ноября 2026 г.

Первичное завершение (Оцененный)

19 декабря 2026 г.

Завершение исследования (Оцененный)

1 февраля 2027 г.

Даты регистрации исследования

Первый отправленный

16 ноября 2026 г.

Впервые представлено, что соответствует критериям контроля качества

16 ноября 2026 г.

Первый опубликованный (Действительный)

20 ноября 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

20 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

16 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕ РЕШЕНО

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться